{"id":"W4291019728","doi":"10.2217/fon-2022-0484","title":"Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Rosetrees Trust; Cancer Research UK","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Internal medicine; Placebo; Clinical trial; Oncology; Extramedullary hematopoiesis; Bone marrow; Haematopoiesis; Pathology; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003557414,0.0006118029,0.001365352,0.0004609035,0.0004566811,0.00002982466,0.0001968813,0.0003275333,0.005497203],"category_scores_gemma":[0.00006628998,0.0005244421,0.000328423,0.000514619,0.0001392119,0.00010901,0.0001998161,0.0006782003,0.0002117855],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002886561,"about_ca_system_score_gemma":0.0010342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003731311,"about_ca_topic_score_gemma":0.0004960012,"domain_scores_codex":[0.9961163,0.0005958824,0.0008407882,0.000981,0.0005057428,0.0009602911],"domain_scores_gemma":[0.9980111,0.0005353927,0.0003139203,0.0005697068,0.0001192401,0.0004506592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1144464,0.1177782,0.1942951,0.0005935633,0.003719964,0.02742101,0.04007006,0.0001237222,0.01071617,0.05464203,0.224584,0.2116098],"study_design_scores_gemma":[0.09103584,0.03152957,0.01785703,0.00007801368,0.0004604751,0.00110888,0.006282044,0.00006997532,0.003775928,0.0001703223,0.8470834,0.0005484995],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9432635,0.001172837,0.000003611887,0.01524702,0.001618992,0.002825734,0.0005351236,0.000161153,0.03517202],"genre_scores_gemma":[0.9817665,0.0006236355,0.0009754239,0.003331976,0.002721996,0.004087188,0.001053983,0.0000996196,0.005339665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6224995,"threshold_uncertainty_score":0.9997207,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02084345738915811,"score_gpt":0.3262002128301859,"score_spread":0.3053567554410278,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}